Biotech Growth Stock Paying a 3.25% Dividend Yield? Is $BMY a Buy?

Today I cover Bristol-Myers Squibb stock analysis. Celgene and Juno Therapeutics were top cancer biotechnology stocks, and both are now owned by BMY. Celgene agreed to buy the rest of Juno Therapeutics it didn’t already own for about $9 billion in cash to gain access to Juno’s pipeline of cancer drugs.The company has been working on an experimental new gene therapy called CAR T-cell therapy — taking a patient’s own immune cells, called T cells, genetically manipulating them to attack specific proteins on cancer, and infusing them back into the patient. CAR T-cell therapy is a highly competitive and potentially lucrative area of biotechnology.

On Nov. 20, 2019 Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company, announced the completion of its $74 billion acquisition of Celgene (NASDAQ:CELG). Bristol-Myers' strategy centers on merging an innovative, agile biotechnology company with the reach and resources of a major pharmaceutical company. Without question, Celgene brings an exciting pipeline, however, it also brings a large drug, Revlimid, that is set to lose its patent protection and face generic competition in the not-so-distant future.

Bristol-Myers paid an attractive price for Celgene. In the two years prior to Bristol-Myers' acquisition of Celgene, Celgene's stock price declined from $119 per share to $67 per share -- a decline of more than 40%. Perhaps even more remarkable is that Celgene traded for just 6.7x forward 12-month earnings, at that point. Thus, Bristol-Myers essentially paid zero premium to acquire Celgene based on its early 2017 valuation.

BMY pays over a 3.25% dividend yield, and I think the stock has solid upside potential.

Resources:

Disclaimer:
I have been investing in the stock market for over 20 years, but I am not a financial advisor or a legal professional, and I am not providing financial or legal advice. The information provided is for informational purposes only. It should not be considered legal or financial advice. You should consult with an attorney or other professional to determine what may be best for your individual needs. FIRED Up Wealth and Eric Cuka do not make any guarantee or other promise as to any results that may be obtained from using our content. No one should make any investment decision without first consulting his or her own financial advisor and conducting his or her own research and due diligence. Past performance is no guarantee of future results.

#stocks #dividends #dividendstocks #dividendgrowthinvesting #biotechstocks #stockmarket #stockstowatch

[joshgo]

I didn't subscribe to other financial channels but i did to you. I like your stock picks and you make every analysis simply clear that everyone can understand imo. Also i think "almost" anything tech related will be big winners in the long run because it's simply the future.

[shapeofsoup]

Whoa, thanks for the shoutout Eric. I really appreciate it. You’re growing a great community here, and I’m glad to be a part of it.

[hristobabrikov]

Nice boost on the price @Mr. FIRED. Bought on 60 and believe BMY is one of the few stocks on the market, which is undervalue + growth prospect. Long BMY

[Mdic]

Great video. Couldnt agee more. As a paramedic. I'm able to see how slowly but surely eloquis Is taking market share from good old Warfarin. Patients dont need to get blood draws all the time etc. Seems like itll be a favourite in the long run.

[Rohit-dqud]

BMY has a great catalog/with wonderful and really effective/useful drugs. Also, they have partnerships galore t/o pharma! Not a day goes by where I'm not writing a BMY Rx... New here, and I really enjoy your genuine and methodical style, and I look forward to taking a dive back into your older vids. Thanks!

[sebastianschlegel]

BMY.. Yeah. Made it a full position this week :) and MDT
EL Schlee

[jessicasmith]

This is very good info, thanks Eric. 🔥🔥

[_snowface_]

Great vídeo! I did not not knew much about BMY aside from the fact that they were merging with celgene. Learned a lot!
I can see it go up if they manage to make the merger work 🤩.
I will add this one to my dgif list asap!

[clownanaround]

Got several shares to start at 57 dollars.

[annedennis]

Thanks for the video. This has been on my "research more" list since your DGIF series. This may be the catalyst I need to do my homework.

[russcannon]

Had this in my watchlist for a few weeks along with MDT. Too many choices lol. Good video bud!

[NeroliDecants]

Awesome video, thank you very much sir. I don't own this one yet but I definitely will look into it more this weekend! Loved the sboutout for Mike.

[TonyMendyk]

just picked some up this week! Giddy up!!

[ab]

Excellent pick! Superb reasoning and supporting material.

[mindsinmotion]

Excellent review. The is a hot stock on the comment section of alot videos

[kevinoconnor]

started a position in this one after doing some more research, thanks Eric

[jayshankarchandran]

Eric Excellent video & analysis on BMY will be adding some to the portfolio , the only pharma i have on my portfolio is Pfizer and has done nothing but stay at the same level. Still don't regret in adding more of FSLY @ $44 but now it is @ $64.

[hodlwaddle]

Just added BMY to my portfolio. Also-. PLEASE, if possible, could you look at HCAT. This was a Sequoia Capital IPO. I think that it is under the radar, in the medical field, and very timely. Thanks.

[tinhnguyen-demary]

Have you look at Merck in the same space with BMY and have #1 cancer drug Keytrda? May be a good player for the long term.!!!

[garyoakham]

Eric can you approve my request to join the Facebook group